Dova Pharmaceuticals, Inc. Common Stock
DOVA
DOVA was delisted on the 11th of November, 2019.
30 hedge funds and large institutions have $135M invested in Dova Pharmaceuticals, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 30 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
23.59% more ownership
Funds ownership: 0% → 23.59% (+24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$41.5M |
| 2 |
Perceptive Advisors
New York
|
+$35.9M |
| 3 |
Fosun International
Hong Kong,
China
|
+$13.7M |
| 4 |
Paulson & Co
New York
|
+$13.1M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$4.21M |
Top Sellers
DOVA Hedge Fund Activity: Q2 2017 in Review
30 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Dova Pharmaceuticals, Inc. Common Stock (DOVA) for Q2 2017, worth a combined $135M.
Buyers outnumbered sellers: 30 funds opened new DOVA positions and 0 closed out — a net gain of 30 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $41.5M.
- 30 institutional investors held Dova Pharmaceuticals, Inc. Common Stock (DOVA) as of Q2 2017, up from 0 in Q1 2017.
- Funds reported $135M of Dova Pharmaceuticals, Inc. Common Stock stock for Q2 2017.
- 30 funds opened new Dova Pharmaceuticals, Inc. Common Stock positions in Q2 2017 and 0 closed out, a net change of +30 holders.
- The largest Dova Pharmaceuticals, Inc. Common Stock buyer in Q2 2017 was Fidelity Investments, an estimated $41.5M added.
Based on aggregated 13F filings for Q2 2017.